查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1872176

单核苷酸多态性（SNP）基因型鉴定：全球市场份额和排名、总收入和需求预测（2025-2031 年）

Single Nucleotide Polymorphism (SNP) Genotyping - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 152 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球单核苷酸多态性（SNP）基因型鉴定市场预计在 2024 年达到 247.1 亿美元，预计到 2031 年将达到 927.5 亿美元，2025 年至 2031 年的复合年增长率为 21.1%。

单核苷酸多态性（SNP）基因型鉴定是一种测量同一物种个体间单核苷酸多态性（SNP）遗传变异的方法。它是一种能够测量更广泛遗传变异的基因型鉴定方法。 SNP基因型鉴定不仅是最常用的遗传标记，也是最有发展前景的遗传标记。它在分子标记开发方面具有巨大的潜力，并且可以大规模自动化操作，因此适用于检测和分析大量的SNP。它被广泛应用于生物学、农业、医学和生物进化等领域。

全球主要企业的SNP基因型鉴定公司包括Illumina、Affymetrix、Applied Biosystems、Agilent Technologies和Beckman Coulter。前五大公司占据了约65%的市场。北美市占率最大，约占40%，其次是欧洲和日本，两者总合约占35%。产品类别包括颠换和转换。按应用领域划分，诊断应用占最大份额，其次是动物、植物和科研。

本报告旨在按地区/国家、类型和应用对全球单核苷酸多态性 (SNP)基因型鉴定市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

本报告根据2020年至2031年的历史数据和预测数据（以2024年为基准年），以销售收入为指标，提供了SNP基因型鉴定市场的规模、估计值和预测。定量和定性分析相结合，有助于读者制定业务/成长策略、评估市场竞争、分析自身在当前市场中的地位，并就SNP基因型鉴定做出明智的商业决策。

市场区隔

公司

  • Illumina
  • Affymetrix
  • Applied Biosystems
  • Agilent Technologies
  • Beckman Coulter
  • Roche
  • Qiagen
  • Luminex Corporation
  • Enzo Life Sciences
  • Bio-rad
  • Sequenom
  • Ocimum Biosolutions
  • GE Healthcare
  • GenScript
  • Douglas Scientific
  • BGI
  • Beijing Sunbiotech
  • HuaGene Biotech
  • Generay Biotech
  • Benegene
  • Shanghai Biochip
  • GENESKY
  • HD Biosciences

按类型分類的细分市场

  • 过渡
  • 颠换

应用领域

  • 诊断
  • 动物
  • 植物
  • 研究
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Single Nucleotide Polymorphism (SNP) Genotyping was estimated to be worth US$ 24710 million in 2024 and is forecast to a readjusted size of US$ 92750 million by 2031 with a CAGR of 21.1% during the forecast period 2025-2031.

Single Nucleotide Polymorphism (SNP) Genotyping is the measurement of genetic variations of single nucleotide polymorphisms (SNPs) between members of a species. It is a form of genotyping, which is the measurement of more general genetic variation. SNP genotyping is not only the genetic markers present in most, but also the most promising markers. SNP genotyping as the most potential for development of molecular markers, it cans achieve large-scale highly automated, thus it is more suited to a huge number of detection and analysis, has been widely used in biology, agriculture, medicine, biological evolution and other fields.

Global Single Nucleotide Polymorphism (SNP) Genotyping key players include Illumina, Affymetrix, Applied Biosystems, Agilent Technologies, Beckman Coulter, etc. Global top five players hold a share about 65%. North America is the largest market, with a share about 40%, followed by Europe and Japan, having a total share about 35 percent. In terms of product, the segment includes Transversion, Transition. And in terms of application, the largest application is Diagnostics, followed by Animal, Plant, Research, etc.

This report aims to provide a comprehensive presentation of the global market for Single Nucleotide Polymorphism (SNP) Genotyping, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Single Nucleotide Polymorphism (SNP) Genotyping by region & country, by Type, and by Application.

The Single Nucleotide Polymorphism (SNP) Genotyping market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Single Nucleotide Polymorphism (SNP) Genotyping.

Market Segmentation

By Company

  • Illumina
  • Affymetrix
  • Applied Biosystems
  • Agilent Technologies
  • Beckman Coulter
  • Roche
  • Qiagen
  • Luminex Corporation
  • Enzo Life Sciences
  • Bio-rad
  • Sequenom
  • Ocimum Biosolutions
  • GE Healthcare
  • GenScript
  • Douglas Scientific
  • BGI
  • Beijing Sunbiotech
  • HuaGene Biotech
  • Generay Biotech
  • Benegene
  • Shanghai Biochip
  • GENESKY
  • HD Biosciences

Segment by Type

  • Transversion
  • Transition

Segment by Application

  • Diagnostics
  • Animal
  • Plant
  • Research
  • Others

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Single Nucleotide Polymorphism (SNP) Genotyping company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Single Nucleotide Polymorphism (SNP) Genotyping in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Single Nucleotide Polymorphism (SNP) Genotyping in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Single Nucleotide Polymorphism (SNP) Genotyping Product Introduction
  • 1.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Market Size Forecast (2020-2031)
  • 1.3 Single Nucleotide Polymorphism (SNP) Genotyping Market Trends & Drivers
    • 1.3.1 Single Nucleotide Polymorphism (SNP) Genotyping Industry Trends
    • 1.3.2 Single Nucleotide Polymorphism (SNP) Genotyping Market Drivers & Opportunity
    • 1.3.3 Single Nucleotide Polymorphism (SNP) Genotyping Market Challenges
    • 1.3.4 Single Nucleotide Polymorphism (SNP) Genotyping Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Players Revenue Ranking (2024)
  • 2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Revenue by Company (2020-2025)
  • 2.3 Key Companies Single Nucleotide Polymorphism (SNP) Genotyping Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Single Nucleotide Polymorphism (SNP) Genotyping Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Single Nucleotide Polymorphism (SNP) Genotyping
  • 2.6 Single Nucleotide Polymorphism (SNP) Genotyping Market Competitive Analysis
    • 2.6.1 Single Nucleotide Polymorphism (SNP) Genotyping Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Single Nucleotide Polymorphism (SNP) Genotyping Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Single Nucleotide Polymorphism (SNP) Genotyping as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Transversion
    • 3.1.2 Transition
  • 3.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type
    • 3.2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, by Type (2020-2031)
    • 3.2.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Diagnostics
    • 4.1.2 Animal
    • 4.1.3 Plant
    • 4.1.4 Research
    • 4.1.5 Others
  • 4.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application
    • 4.2.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, by Application (2020-2031)
    • 4.2.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region
    • 5.1.1 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2020-2025)
    • 5.1.3 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2026-2031)
    • 5.1.4 Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 5.2.2 North America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 5.3.2 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 5.5.2 South America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.3.2 United States Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.4.2 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.5.2 China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.6.2 Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.7.2 South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020-2031
    • 6.9.2 India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Illumina
    • 7.1.1 Illumina Profile
    • 7.1.2 Illumina Main Business
    • 7.1.3 Illumina Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.1.4 Illumina Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Illumina Recent Developments
  • 7.2 Affymetrix
    • 7.2.1 Affymetrix Profile
    • 7.2.2 Affymetrix Main Business
    • 7.2.3 Affymetrix Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.2.4 Affymetrix Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Affymetrix Recent Developments
  • 7.3 Applied Biosystems
    • 7.3.1 Applied Biosystems Profile
    • 7.3.2 Applied Biosystems Main Business
    • 7.3.3 Applied Biosystems Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.3.4 Applied Biosystems Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Applied Biosystems Recent Developments
  • 7.4 Agilent Technologies
    • 7.4.1 Agilent Technologies Profile
    • 7.4.2 Agilent Technologies Main Business
    • 7.4.3 Agilent Technologies Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.4.4 Agilent Technologies Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Agilent Technologies Recent Developments
  • 7.5 Beckman Coulter
    • 7.5.1 Beckman Coulter Profile
    • 7.5.2 Beckman Coulter Main Business
    • 7.5.3 Beckman Coulter Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.5.4 Beckman Coulter Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Beckman Coulter Recent Developments
  • 7.6 Roche
    • 7.6.1 Roche Profile
    • 7.6.2 Roche Main Business
    • 7.6.3 Roche Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.6.4 Roche Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Roche Recent Developments
  • 7.7 Qiagen
    • 7.7.1 Qiagen Profile
    • 7.7.2 Qiagen Main Business
    • 7.7.3 Qiagen Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.7.4 Qiagen Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Qiagen Recent Developments
  • 7.8 Luminex Corporation
    • 7.8.1 Luminex Corporation Profile
    • 7.8.2 Luminex Corporation Main Business
    • 7.8.3 Luminex Corporation Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.8.4 Luminex Corporation Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Luminex Corporation Recent Developments
  • 7.9 Enzo Life Sciences
    • 7.9.1 Enzo Life Sciences Profile
    • 7.9.2 Enzo Life Sciences Main Business
    • 7.9.3 Enzo Life Sciences Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.9.4 Enzo Life Sciences Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Enzo Life Sciences Recent Developments
  • 7.10 Bio-rad
    • 7.10.1 Bio-rad Profile
    • 7.10.2 Bio-rad Main Business
    • 7.10.3 Bio-rad Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.10.4 Bio-rad Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Bio-rad Recent Developments
  • 7.11 Sequenom
    • 7.11.1 Sequenom Profile
    • 7.11.2 Sequenom Main Business
    • 7.11.3 Sequenom Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.11.4 Sequenom Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Sequenom Recent Developments
  • 7.12 Ocimum Biosolutions
    • 7.12.1 Ocimum Biosolutions Profile
    • 7.12.2 Ocimum Biosolutions Main Business
    • 7.12.3 Ocimum Biosolutions Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.12.4 Ocimum Biosolutions Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Ocimum Biosolutions Recent Developments
  • 7.13 GE Healthcare
    • 7.13.1 GE Healthcare Profile
    • 7.13.2 GE Healthcare Main Business
    • 7.13.3 GE Healthcare Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.13.4 GE Healthcare Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.13.5 GE Healthcare Recent Developments
  • 7.14 GenScript
    • 7.14.1 GenScript Profile
    • 7.14.2 GenScript Main Business
    • 7.14.3 GenScript Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.14.4 GenScript Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.14.5 GenScript Recent Developments
  • 7.15 Douglas Scientific
    • 7.15.1 Douglas Scientific Profile
    • 7.15.2 Douglas Scientific Main Business
    • 7.15.3 Douglas Scientific Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.15.4 Douglas Scientific Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Douglas Scientific Recent Developments
  • 7.16 BGI
    • 7.16.1 BGI Profile
    • 7.16.2 BGI Main Business
    • 7.16.3 BGI Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.16.4 BGI Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.16.5 BGI Recent Developments
  • 7.17 Beijing Sunbiotech
    • 7.17.1 Beijing Sunbiotech Profile
    • 7.17.2 Beijing Sunbiotech Main Business
    • 7.17.3 Beijing Sunbiotech Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.17.4 Beijing Sunbiotech Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.17.5 Beijing Sunbiotech Recent Developments
  • 7.18 HuaGene Biotech
    • 7.18.1 HuaGene Biotech Profile
    • 7.18.2 HuaGene Biotech Main Business
    • 7.18.3 HuaGene Biotech Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.18.4 HuaGene Biotech Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.18.5 HuaGene Biotech Recent Developments
  • 7.19 Generay Biotech
    • 7.19.1 Generay Biotech Profile
    • 7.19.2 Generay Biotech Main Business
    • 7.19.3 Generay Biotech Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.19.4 Generay Biotech Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.19.5 Generay Biotech Recent Developments
  • 7.20 Benegene
    • 7.20.1 Benegene Profile
    • 7.20.2 Benegene Main Business
    • 7.20.3 Benegene Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.20.4 Benegene Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.20.5 Benegene Recent Developments
  • 7.21 Shanghai Biochip
    • 7.21.1 Shanghai Biochip Profile
    • 7.21.2 Shanghai Biochip Main Business
    • 7.21.3 Shanghai Biochip Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.21.4 Shanghai Biochip Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.21.5 Shanghai Biochip Recent Developments
  • 7.22 GENESKY
    • 7.22.1 GENESKY Profile
    • 7.22.2 GENESKY Main Business
    • 7.22.3 GENESKY Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.22.4 GENESKY Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.22.5 GENESKY Recent Developments
  • 7.23 HD Biosciences
    • 7.23.1 HD Biosciences Profile
    • 7.23.2 HD Biosciences Main Business
    • 7.23.3 HD Biosciences Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
    • 7.23.4 HD Biosciences Single Nucleotide Polymorphism (SNP) Genotyping Revenue (US$ Million) & (2020-2025)
    • 7.23.5 HD Biosciences Recent Developments

8 Industry Chain Analysis

  • 8.1 Single Nucleotide Polymorphism (SNP) Genotyping Industrial Chain
  • 8.2 Single Nucleotide Polymorphism (SNP) Genotyping Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Single Nucleotide Polymorphism (SNP) Genotyping Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Single Nucleotide Polymorphism (SNP) Genotyping Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Single Nucleotide Polymorphism (SNP) Genotyping Market Trends
  • Table 2. Single Nucleotide Polymorphism (SNP) Genotyping Market Drivers & Opportunity
  • Table 3. Single Nucleotide Polymorphism (SNP) Genotyping Market Challenges
  • Table 4. Single Nucleotide Polymorphism (SNP) Genotyping Market Restraints
  • Table 5. Global Single Nucleotide Polymorphism (SNP) Genotyping Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Single Nucleotide Polymorphism (SNP) Genotyping Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Single Nucleotide Polymorphism (SNP) Genotyping Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Single Nucleotide Polymorphism (SNP) Genotyping Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Single Nucleotide Polymorphism (SNP) Genotyping
  • Table 10. Global Single Nucleotide Polymorphism (SNP) Genotyping Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Single Nucleotide Polymorphism (SNP) Genotyping as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Illumina Basic Information List
  • Table 32. Illumina Description and Business Overview
  • Table 33. Illumina Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Illumina (2020-2025)
  • Table 35. Illumina Recent Developments
  • Table 36. Affymetrix Basic Information List
  • Table 37. Affymetrix Description and Business Overview
  • Table 38. Affymetrix Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Affymetrix (2020-2025)
  • Table 40. Affymetrix Recent Developments
  • Table 41. Applied Biosystems Basic Information List
  • Table 42. Applied Biosystems Description and Business Overview
  • Table 43. Applied Biosystems Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Applied Biosystems (2020-2025)
  • Table 45. Applied Biosystems Recent Developments
  • Table 46. Agilent Technologies Basic Information List
  • Table 47. Agilent Technologies Description and Business Overview
  • Table 48. Agilent Technologies Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Agilent Technologies (2020-2025)
  • Table 50. Agilent Technologies Recent Developments
  • Table 51. Beckman Coulter Basic Information List
  • Table 52. Beckman Coulter Description and Business Overview
  • Table 53. Beckman Coulter Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Beckman Coulter (2020-2025)
  • Table 55. Beckman Coulter Recent Developments
  • Table 56. Roche Basic Information List
  • Table 57. Roche Description and Business Overview
  • Table 58. Roche Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Roche (2020-2025)
  • Table 60. Roche Recent Developments
  • Table 61. Qiagen Basic Information List
  • Table 62. Qiagen Description and Business Overview
  • Table 63. Qiagen Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Qiagen (2020-2025)
  • Table 65. Qiagen Recent Developments
  • Table 66. Luminex Corporation Basic Information List
  • Table 67. Luminex Corporation Description and Business Overview
  • Table 68. Luminex Corporation Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Luminex Corporation (2020-2025)
  • Table 70. Luminex Corporation Recent Developments
  • Table 71. Enzo Life Sciences Basic Information List
  • Table 72. Enzo Life Sciences Description and Business Overview
  • Table 73. Enzo Life Sciences Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Enzo Life Sciences (2020-2025)
  • Table 75. Enzo Life Sciences Recent Developments
  • Table 76. Bio-rad Basic Information List
  • Table 77. Bio-rad Description and Business Overview
  • Table 78. Bio-rad Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Bio-rad (2020-2025)
  • Table 80. Bio-rad Recent Developments
  • Table 81. Sequenom Basic Information List
  • Table 82. Sequenom Description and Business Overview
  • Table 83. Sequenom Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Sequenom (2020-2025)
  • Table 85. Sequenom Recent Developments
  • Table 86. Ocimum Biosolutions Basic Information List
  • Table 87. Ocimum Biosolutions Description and Business Overview
  • Table 88. Ocimum Biosolutions Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Ocimum Biosolutions (2020-2025)
  • Table 90. Ocimum Biosolutions Recent Developments
  • Table 91. GE Healthcare Basic Information List
  • Table 92. GE Healthcare Description and Business Overview
  • Table 93. GE Healthcare Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of GE Healthcare (2020-2025)
  • Table 95. GE Healthcare Recent Developments
  • Table 96. GenScript Basic Information List
  • Table 97. GenScript Description and Business Overview
  • Table 98. GenScript Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of GenScript (2020-2025)
  • Table 100. GenScript Recent Developments
  • Table 101. Douglas Scientific Basic Information List
  • Table 102. Douglas Scientific Description and Business Overview
  • Table 103. Douglas Scientific Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Douglas Scientific (2020-2025)
  • Table 105. Douglas Scientific Recent Developments
  • Table 106. BGI Basic Information List
  • Table 107. BGI Description and Business Overview
  • Table 108. BGI Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of BGI (2020-2025)
  • Table 110. BGI Recent Developments
  • Table 111. Beijing Sunbiotech Basic Information List
  • Table 112. Beijing Sunbiotech Description and Business Overview
  • Table 113. Beijing Sunbiotech Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 114. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Beijing Sunbiotech (2020-2025)
  • Table 115. Beijing Sunbiotech Recent Developments
  • Table 116. HuaGene Biotech Basic Information List
  • Table 117. HuaGene Biotech Description and Business Overview
  • Table 118. HuaGene Biotech Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 119. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of HuaGene Biotech (2020-2025)
  • Table 120. HuaGene Biotech Recent Developments
  • Table 121. Generay Biotech Basic Information List
  • Table 122. Generay Biotech Description and Business Overview
  • Table 123. Generay Biotech Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 124. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Generay Biotech (2020-2025)
  • Table 125. Generay Biotech Recent Developments
  • Table 126. Benegene Basic Information List
  • Table 127. Benegene Description and Business Overview
  • Table 128. Benegene Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 129. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Benegene (2020-2025)
  • Table 130. Benegene Recent Developments
  • Table 131. Shanghai Biochip Basic Information List
  • Table 132. Shanghai Biochip Description and Business Overview
  • Table 133. Shanghai Biochip Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 134. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of Shanghai Biochip (2020-2025)
  • Table 135. Shanghai Biochip Recent Developments
  • Table 136. GENESKY Basic Information List
  • Table 137. GENESKY Description and Business Overview
  • Table 138. GENESKY Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 139. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of GENESKY (2020-2025)
  • Table 140. GENESKY Recent Developments
  • Table 141. HD Biosciences Basic Information List
  • Table 142. HD Biosciences Description and Business Overview
  • Table 143. HD Biosciences Single Nucleotide Polymorphism (SNP) Genotyping Products, Services and Solutions
  • Table 144. Revenue (US$ Million) in Single Nucleotide Polymorphism (SNP) Genotyping Business of HD Biosciences (2020-2025)
  • Table 145. HD Biosciences Recent Developments
  • Table 146. Key Raw Materials Lists
  • Table 147. Raw Materials Key Suppliers Lists
  • Table 148. Single Nucleotide Polymorphism (SNP) Genotyping Downstream Customers
  • Table 149. Single Nucleotide Polymorphism (SNP) Genotyping Distributors List
  • Table 150. Research Programs/Design for This Report
  • Table 151. Key Data Information from Secondary Sources
  • Table 152. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Single Nucleotide Polymorphism (SNP) Genotyping Product Picture
  • Figure 2. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Single Nucleotide Polymorphism (SNP) Genotyping Report Years Considered
  • Figure 5. Global Single Nucleotide Polymorphism (SNP) Genotyping Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Single Nucleotide Polymorphism (SNP) Genotyping Revenue in 2024
  • Figure 7. Single Nucleotide Polymorphism (SNP) Genotyping Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Transversion Picture
  • Figure 9. Transition Picture
  • Figure 10. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Diagnostics
  • Figure 13. Product Picture of Animal
  • Figure 14. Product Picture of Plant
  • Figure 15. Product Picture of Research
  • Figure 16. Product Picture of Others
  • Figure 17. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 18. Global Single Nucleotide Polymorphism (SNP) Genotyping Sales Value Market Share by Application, 2024 & 2031
  • Figure 19. North America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (2020-2031) & (US$ Million)
  • Figure 20. North America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031
  • Figure 21. Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 22. Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031
  • Figure 23. Asia Pacific Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 24. Asia Pacific Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Region (%), 2024 VS 2031
  • Figure 25. South America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 26. South America Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031
  • Figure 27. Middle East & Africa Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. Middle East & Africa Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Country (%), 2024 VS 2031
  • Figure 29. Key Countries/Regions Single Nucleotide Polymorphism (SNP) Genotyping Sales Value (%), (2020-2031)
  • Figure 30. United States Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. United States Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
  • Figure 32. United States Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (%), 2024 VS 2031
  • Figure 33. Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
  • Figure 35. Europe Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (%), 2024 VS 2031
  • Figure 36. China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
  • Figure 38. China Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (%), 2024 VS 2031
  • Figure 39. Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
  • Figure 41. Japan Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (%), 2024 VS 2031
  • Figure 42. South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
  • Figure 44. South Korea Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (%), 2024 VS 2031
  • Figure 45. Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
  • Figure 47. Southeast Asia Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (%), 2024 VS 2031
  • Figure 48. India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value, (2020-2031) & (US$ Million)
  • Figure 49. India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Type (%), 2024 VS 2031
  • Figure 50. India Single Nucleotide Polymorphism (SNP) Genotyping Sales Value by Application (%), 2024 VS 2031
  • Figure 51. Single Nucleotide Polymorphism (SNP) Genotyping Industrial Chain
  • Figure 52. Single Nucleotide Polymorphism (SNP) Genotyping Manufacturing Cost Structure
  • Figure 53. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 54. Bottom-up and Top-down Approaches for This Report
  • Figure 55. Data Triangulation
  • Figure 56. Key Executives Interviewed